Version May 2024
Allergic conjunctivitis: Ophthalmic: Instill 1 drop into each eye twice daily. Continue throughout period of exposure, even in the absence of symptoms.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
Refer to adult dosing.
(For additional information see "Epinastine: Pediatric drug information")
Allergic conjunctivitis: Children ≥2 years and Adolescents: Ophthalmic: Instill 1 drop into each eye twice daily; continue throughout period of exposure, even in the absence of symptoms.
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Frequency not always defined.
1% to 10%:
Central nervous system: Headache (1% to 3%)
Infection: Infection (10%; defined as cold symptoms and upper respiratory tract infection)
Ophthalmic: Burning sensation of eyes, eye pruritus, follicular conjunctivitis, ocular hyperemia
Respiratory: Cough (1% to 3%), pharyngitis (1% to 3%), rhinitis (1% to 3%), sinusitis (1% to 3%)
<1%, postmarketing, and/or case reports: Increased lacrimation
There are no contraindications listed in the manufacturer's labeling.
Concerns related to adverse effects:
• Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.
Special populations:
• Contact lens wearers: Contains benzalkonium chloride which may be absorbed by contact lenses; remove contact lenses prior to use and wait 10 minutes before reinserting.
Other warnings/precautions:
• Appropriate use: For topical ophthalmic use only. Not for the treatment of contact lens irritation; do not wear contact lenses if eye is red.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic, as hydrochloride:
Generic: 0.05% (5 mL)
Yes
Solution (Epinastine HCl Ophthalmic)
0.05% (per mL): $20.52 - $21.40
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
For ophthalmic use only; avoid touching tip of applicator to eye or other surfaces. Contact lenses should be removed prior to application, may be reinserted after 10 minutes. Do not wear contact lenses if eyes are red.
For ophthalmic use only; avoid touching tip of applicator to eye or other surfaces. Contact lenses should be removed prior to application; may be reinserted after 10 minutes. Do not wear contact lenses if eyes are red.
Allergic conjunctivitis: Prevention of itching of the eye associated with allergic conjunctivitis.
None known.
There are no known significant interactions.
Adverse events were observed in some animal reproduction studies.
It is not known if epinastine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering epinastine to nursing women.
Selective H1-receptor antagonist; inhibits release of histamine from the mast cell; also has affinity for the H2, alpha1, alpha2, and the 5-HT2 receptors
Onset of action: 3 to 5 minutes.
Duration: 8 hours.
Absorption: Low systemic absorption following topical application.
Distribution: Does not cross blood-brain barrier.
Protein binding: 64%.
Metabolism: <10% metabolized.
Half-life elimination: Terminal: ~12 hours.
Excretion: IV: Urine (~55% as unchanged drug); feces (~30%).
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
